Drug Trial Radar · NCT06165965
To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008
Last checked: Nov 19, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
May 3, 2022
Primary completion
Jun 13, 2022
Study completion Jun 27, 2022
Sponsor
- Lead sponsor
- Jeil Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the safety and pharmacokinetic characteristics after the administration of JT-001, JT-002 and JLP-2008
Conditions
- Healthy Adult
Interventions
SGLT2 inhibitorDrug
SGLT2 dual inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC over24H of JLP-2008Time frame: 24 hours
- Cmax of JLP-2008Time frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bundang CHA university global clinical trials center Institutional Review Board
Gyeonggi-do, Bundang-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.